Comprehensive analysis of microRNA-regulated protein interaction network reveals the tumor suppressive role of microRNA-149 in human hepatocellular carcinoma via targeting AKT-mTOR pathway by Yanqiong Zhang et al.
Zhang et al. Molecular Cancer 2014, 13:253
http://www.molecular-cancer.com/content/13/1/253RESEARCH Open AccessComprehensive analysis of microRNA-regulated
protein interaction network reveals the tumor
suppressive role of microRNA-149 in human
hepatocellular carcinoma via targeting
AKT-mTOR pathway
Yanqiong Zhang1†, Xiaodong Guo2†, Lu Xiong3, Lingxiang Yu2, Zhiwei Li2, Qiuyan Guo1, Zhiyan Li2, Boan Li2*
and Na Lin1*Abstract
Background: Our previous study identified AKT1, AKT2 and AKT3 as unfavorable prognostic factors for patients
with hepatocellular carcinoma (HCC). However, limited data are available on their exact mechanisms in HCC. Since
microRNAs (miRNAs) are implicated in various human cancers including HCC, we aimed to screen miRNAs targeting
AKTs and investigate their underlying mechanisms in HCC by integrating bioinformatics prediction, network
analysis, functional assay and clinical validation.
Methods: Five online programs of miRNA target prediction and RNAhybrid which calculate the minimum free
energy (MFE) of the duplex miRNA:mRNA were used to screen optimized miRNA-AKT interactions. Then,
miRNA-regulated protein interaction network was constructed and 5 topological features (‘Degree’, ‘Node-betweenness’,
‘Edge-betweenness’, ‘Closeness’ and ‘Modularity’) were analyzed to link candidate miRNA-AKT interactions to
oncogenesis and cancer hallmarks. Further systematic experiments were performed to validate the prediction results.
Results: Six optimized miRNA-AKT interactions (miR-149-AKT1, miR-302d-AKT1, miR-184-AKT2, miR-708-AKT2,
miR-122-AKT3 and miR-124-AKT3) were obtained by combining the miRNA target prediction and MFE calculation.
Then, 103 validated targets for the 6 candidate miRNAs were collected from miRTarBase. According to the enrichment
analysis on GO items and KEGG pathways, these validated targets were significantly enriched in many known
oncogenic pathways for HCC. In addition, miRNA-regulated protein interaction network were divided into 5 functional
modules. Importantly, AKT1 and its interaction with mTOR respectively had the highest node-betweenness and
edge-betweenness, implying their bottleneck roles in the network. Further experiments confirmed that miRNA-149
directly targeted AKT1 in HCC by a miRNA luciferase reporter approach. Then, re-expression of miR-149 significantly
inhibited HCC cell proliferation and tumorigenicity by regulating AKT1/mTOR pathway. Notably, miR-149 down-regulation
in clinical HCC tissues was correlated with tumor aggressiveness and poor prognosis of patients.
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Conclusion: This comprehensive analysis identified a list of miRNAs targeting AKTs and revealed their critical roles in HCC
malignant progression. Especially, miR-149 may function as a tumor suppressive miRNA and play an important role in
inhibiting the HCC tumorigenesis by modulating the AKT/mTOR pathway. Our clinical evidence also highlight the
prognostic potential of miR-149 in HCC. The newly identified miR-149/AKT/mTOR axis might be a promising therapeutic
target in the prevention and treatment of HCC.
Keywords: Hepatocellular carcinoma, microRNA-regulated protein interaction network, microRNA-149, AKT/mTOR
pathway, PrognosisBackground
Hepatocellular carcinoma (HCC) ranks as the fifth
(seventh) most prevalent malignancy and the second
(sixth) leading cause of cancer-related deaths in men
(women), accounting for approximately 695,900 deaths
per year worldwide [1]. The hepatocarcinogenesis is a
multi-step process from chronic hepatitis, cirrhosis and
dysplastic nodules to malignant tumors [2]. Despite the
great advancement of numerous therapeutic strategies,
HCC remains a major public health concern due to fast
infiltrating growth, early metastasis, high-grade malig-
nancy, and poor prognosis. More than two-thirds of HCC
patients occur recurrence after surgical hepatic resection
[3]. The overall 5-year survival rate for these patients is
still only 5% [4]. Growing clinical observations indicate
that HCC patients with the same clinicopathologic
features often display different outcome, suggesting that
there may be several complex molecular and cellular
events involved in the development and aggressive pro-
gression of HCC. Therefore, it is of crucial significance to
investigate the molecular pathogenesis of HCC in order to
develop novel therapeutic strategies for the treatment of
this disease.
MicroRNAs (miRNAs) represent a group of short non-
coding RNA molecules with 18–25 nucleotides in length
[5]. Based on miRBase (release 21), the human genome
encodes 1881 (2588) precursor (mature) miRNAs, which
potentially target the majority of the human genes [6].
Functionally, miRNAs transcriptionally or post-transcrip-
tionally suppress the expression of their target genes at
mRNA or protein levels in many organisms, such as yeast,
fruit flies, worms, vertebrates, human and plants by
imperfect basepairing with the 3′untranslated regions
(3′UTRs) of target genes [7], and play important roles in
regulating diverse biological processes, including develop-
ment, cell cycle, proliferation, differentiation, apoptosis
and response to stress [8]. In recent years, accumulating
evidence have also indicated that the dysregulation of
miRNAs in various human cancers may modulate tumor
cell proliferation, tumor angiogenesis, invasion and metas-
tasis during tumor initiation and progression [9]. Accor-
ding to the functions of their target genes, miRNAs either
act as oncomiRs or as tumor suppressors [10]. Since agrowing number of HCC-related genes have been demon-
strated to be regulated by miRNAs, it is not surprising that
changes in the endogenous expression of miRNAs may be
one of the most crucial mechanisms in the hepatocar-
cinogenesis. For example, miR-105 has been reported to
function as a potential tumor suppressor and inhibit cell
proliferation by regulating the PI3K/AKT signaling path-
way in human HCC [11]; Tan and colleagues identified a
serum of miRNA panel (hsa-miR-206, hsa-miR-141-3p,
hsa-miR-433-3p, hsa-miR-1228-5p, hsa-miR-199a-5p, hsa-
miR-122-5p, hsa-miR-192-5p, and hsa-miR-26a-5p) that
has considerable clinical value in HCC diagnosis [12]; The
presence of miR-101 has also been indicated to be a bio-
chemical marker for monitoring the progression of tumor
development in HBV-related HCC, and to be a potential
prognostic marker and therapeutic target for HCC [13].
These previous findings highlight the central and potential
roles of miRNAs in the pathogenesis of HCC and elucidate
new possibilities that may be useful as diagnostic and
prognostic markers, as well as novel therapeutic targets in
HCC. However, the existing knowledge of miRNA alter-
ations in human HCC remains limited.
MiRNAs have been demonstrated to function in a
multiple-to-multiple relationship with their target genes,
which means that a specific miRNA can regulate expres-
sion of up to thousand mRNAs, and a specific mRNA
can be regulated by multiple miRNAs, implying that the
interference of miRNAs in biological processes is quite
complicated [14]. Since miRNAs and their target
mRNAs function cooperatively, we should construct the
miRNAs regulatory networks in order to scrutinize the
effects of miRNAs by the network-based systems bio-
logy approaches. Our previous study combined expres-
sion profile, interaction network analysis and clinical
validation to identify three AKT kinase family members
(AKT1 ~ AKT3) as unfavorable prognostic factors for
HCC patients [15]. However, limited data are available
on their exact mechanisms in this cancer. To investigate
this issue, we here performed a comprehensive analysis
by integrating bioinformatics prediction of miRNAs
targeting AKTs, miRNAs-regulated protein interaction
network construction and topological analysis, and
extensive validation on the miRNA-AKT functional
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as shown in Figure 1.
Results
Candidate miRNAs targeting AKTs
A total of 29 miRNAs were predicted to respectively target
AKT1, AKT2 and AKT3 by more than 3 out of 5 differentFigure 1 A schematic diagram of this comprehensive analysis.programs (TargetScan, miRDB, DIANA-microT, miRanda
and miRWalk) were listed in Additional file 1: Table S1.
Then, RNAhybrid was used to calculate the hybridization
free energy of the duplex miRNA:mRNA. The candidate
miRNAs were thus confirmed according to the minimum
free energy (MFE) values of their interactions with AKTs.
As shown in Additional file 2: Table S2, 6 optimized
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AKT1, miR-184-AKT2, miR-708-AKT2, miR-122-AKT3
and miR-124-AKT3) had lower MFEs than the median
values [−33.35(kcal/mol)] of all MFEs, thus, miR-149 and
miR-302d were identified as candidate miRNAs targeting
AKT1, miR-184 and miR-708 were identified as candidate
miRNAs targeting AKT2, and miR-122 and miR-124 were
identified as candidate miRNAs targeting AKT3.
Enrichment analysis of validated targets for candidate
miRNAs
To elucidate the functions of 6 candidate miRNAs, 103
validated targets for them were collected from miRTar-
Base. Please see detail information on these validated
targets in Additional file 3: Table S3. Then, the enrich-
ment analysis based on GO annotation system was per-
formed. This system uses a controlled and hierarchical
vocabulary to assign function to genes or gene products
in any organism. As shown in Additional file 4: Figure
S1A, the validated targets for 6 candidate miRNAs had
enriched GO terms related to apoptosis, cell death, and
cell cycle. In terms of pathway information which is im-
portant for understanding gene and protein function,
the validated targets were significantly enriched in many
known oncogenic pathways for HCC, such as focal
adhesion, cell cycle, p53 signaling pathway, mTOR sig-
naling pathway, apoptosis, VEGF signaling pathway, etc.
(Additional file 4: Figure S1B).
Network analysis
The interaction information of proteins encoded by
validated targets of 6 candidate miRNAs were used to
construct candidate miRNAs-regulated protein inter-
action network, which consists of 2868 nodes and 4779
edges. Please see detail information on this network in
Additional file 5: Table S4.
Hub proteins in the protein interaction networks have
extremely high levels of degree and tend to encode
essential genes. According to the previous studies of Li
et al. [16] and our research group [15,17], we identified a
node as a hub protein if its degree is more than 2 fold of
the median degree of all nodes in a network. As a result,
113 nodes were identified as hub proteins. Then, we
constructed the interaction network of these hub pro-
teins, which consists of 99 nodes and 355 edges as
shown in Figure 2A. Please see detail information on this
network in Additional file 6: Table S5.
Three topological features, ‘Degree’, ‘Node betweenness’
and ‘Closeness’ (defined in ‘Materials and methods’
section) were chosen to identify topological important
nodes. After calculating the value of the 3 features for
each hub node, the median values of ‘Degree’, ‘Node bet-
weenness’ and ‘Closeness’ were 7, 1.07 and 38.13, respec-
tively. Therefore, we determined that hub nodes with‘Degree’ > 7, ‘Node betweenness’ > 1.07, and ‘Closeness’ >
38.13 were topological important nodes. As a result,
28 topological important nodes were selected (Additional
file 7: Table S6). Among them, 16 (AKT1, AKT2, AKT3,
AR, CDK2, CDK4, CDK6, E2F1, IGF1R, MYBL2, NR3C1,
PTPN1, RAC1, RELA, RHOA and SOCS1) were validated
targets for candidate miRNAs targeting AKTs.
Modularity has been reported to be another important
aspect of a protein interaction network. Nodes that are
highly interconnected within the network are usually in-
volved in the same biological modules or pathways. Using
Markov clustering algorithm, we divided the interaction
network of hub proteins into 5 functional modules con-
taining 72, 10, 9, 4 and 4 nodes, respectively (Figure 2B).
According to the enrichment analysis based on Gene
Ontology (GO) annotation system and KEGG pathway,
the biggest functional module was significantly associated
with PI3K/AKT/mTOR signaling pathway, MAPK signal-
ing pathway, cell cycle, focal adhesion and Wnt signaling
pathway. The other modules were respectively involved in
G1/S transition of mitotic cell cycle, regulation of gene ex-
pression, apoptosis and Notching signaling pathway.
Since an interaction with a high ‘edge-betweenness’ has
been defined as a bottleneck which has many ‘shortest
paths’ going through it and controls the rate of information
flow, we further calculated the ‘edge-betweenness’ of each
interaction in the interaction network of hub proteins. As
shown in Additional file 8: Table S7, the interaction bet-
ween AKT1-mTOR had the highest edge-betweenness
value (164.38), suggesting its importance in connecting dif-
ferent modules in the network.
Taken together, the above network analysis showed that
AKT1 and its interaction with mTOR respectively had the
highest node-betweenness and edge-betweenness, imply-
ing their bottleneck roles in the network. According to the
combination of the miRNA target prediction and MFE
calculation, miR-149 and miR-302d were identified as can-
didate miRNAs targeting AKT1. Pan et al. [18] reported
the regulatory effect of miR-149 on AKT1 in glioma cells.
Lin et al. [19] also identified AKT1 as a direct target of
miR-149* in various cancer cells, including neuroblastoma
and Hela cells. However, the interaction between miR-149
and AKT1 has not been validated in HCC cells. In
addition, the regulatory effect of miR-302d on AKT1 has
not been reported previously. On this context, we would
like to perform extensive experiments to confirm the miR-
149-AKT1-mTOR axis and its clinical relevance in human
HCC.
Experimental validation
MiRNA-149 directly targets AKT1 in HCC cells
To verify the regulatory effect of miR-149 on AKT1 in
HCC cells, we transfected HepG2 cells with miR-149
mimics, miR-149 mimic control (negative control, NC),
Figure 2 Candidate miRNAs regulated protein interaction networks. (A) Interaction network of hub nodes in the candidate miRNAs regulated
protein interaction networks. Nodes with yellow rings refer to the validated targets of hsa-miR-149, hsa-miR-302d, hsa-miR-184, hsa-miR-708,
hsa-miR-122 and hsa-miR-124. (B) Five functional modules of interaction network of hub nodes in the candidate miRNAs regulated protein
interaction networks.
Zhang et al. Molecular Cancer 2014, 13:253 Page 5 of 15
http://www.molecular-cancer.com/content/13/1/253and blank control culture medium (mock). After 24 h
post-transfection, the expression level of AKT1 protein in
HepG2 cells overexpressed miR-149 was significantly
lower than those in NC and mock groups (both P < 0.001,
Figure 3A~C).
To verify whether AKT1 was a direct target of miR-149,
the luciferase reporter containing the complimentary seed
sequence of miR-149 at the 3′-UTR region of AKT1mRNA was constructed (Figure 3D). Luciferase activity
was detected at 48 h after the co-transfection of FLuci vec-
tor (3′-UTR-AKT1wt FLuci vector or 3′-UTR-AKT1mut
FLuci vector), miR-149 mimic or NC mimic, and RLuci
vector in HepG2 cells. As shown in Figure 3E, the lucifer-
ase activity was significantly decreased in HepG2 cells
co-transfected with 3′-UTR-AKT1wt FLuci vector and
miR-149 mimic compared with those co-transfected with
Figure 3 MiRNA-149 directly targets AKT1 in HCC cells. (A) QRT-PCR analysis showing relative expression of miR-149 in HepG2 cells transfected
with miR-149 mimics, miR-149 mimic control (negative control, NC), and blank control culture medium (mock). (B, C and F) Relative expression of
AKT1, p-AKT1, mTOR and p-mTOR proteins in HepG2 cells transfected with miR-149 mimics, miR-149 mimic control (negative control, NC), and blank
control culture medium (mock) detected by Western blot analysis. GAPDH was used as an internal loading control. (D) RNA sequence alignment
showing the 3′-UTR of AKT1 mRNA contains a complementary site for the seed region of miR-149. AKT1mut is amutant with substitutions in the
complementary region as a negative control. (E) Luciferase report assay was performed to verify whether AKT1 was a direct target of miR-149. The
luciferase activity was detected after transfection of FLuci vector (3′-UTR-AKT1wt FLuci vector or 3′-UTR-AKT1mut FLuci vector) into the miR-149 mimic
or miR-149 mimic control (negative control, NC) transfected HepG2 cells.
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(P = 0.006), suggesting that the fragment at the 3′-UTR of
the AKT1 mRNA was the complementary site for the
miRNA-149 seed region, and thus, that AKT1 was a direct
target of miR-149.
MiR-149 regulates the AKT1/mTOR pathway in HCC cells
To verify the regulatory effect of miR-149 in AKT/mTOR
pathway, we examined the expression of key components
in this pathway, including AKT1, pAKT1, mTOR and
pmTOR, in HepG2 cells with or without miR-149 overex-
pression. As shown in Figure 3B and F, the total and phos-
phorylated protein expression levels of AKT1 and mTOR
were all significantly decreased in HepG2 cells overex-
pressed miR-149 (all P < 0.001), indicating that miR-149
might be an important regulator of this signaling pathway.
Reverse correlation between miR-149 and AKT1 mRNA
expression in human HCC tissues and cells
QRT-PCR was performed to evaluate the relationship
between miR-149 and AKT1 mRNA expression in HCC
tissues and cells in vitro. As shown in Figure 4A and B,
the expression level of miR-149 in HCC tissues was sig-
nificantly lower than that in adjacent nonneoplastic
liver tissues (P < 0.001, Figure 4A), while AKT1 mRNA
expression was dramatically increased in HCC tissuescompared to adjacent nonneoplastic liver tissues (P < 0.001,
Figure 4B), which was similar to our previous study on the
expression levels of AKT1 protein by immunohistoche-
mistry (IHC) analysis based on the same cohort of HCC
patients (IHC scores of AKT1 protein in HCC tissues vs.
adjacent nonneoplastic liver tissues, mean ± S.D.: 6.32 ±
1.74 vs. 2.48 ± 0.29, P < 0.001) [15]. More interestingly, the
Spearman Correlation analysis clearly showed negative
correlations between miR-149 and AKT1 mRNA (protein,
IHC scores) expression in HCC tissues (for miR-149 and
AKT1 mRNA: rs = −0.639, P < 0.001, Figure 4C; for miR-
149 and AKT1 protein: rs = −0.716, P < 0.001, Figure 4D).
These findings were consistent with those based on HCC
cells in vitro system (Figure 4E ~ F).
MiR-149 inhibits cell proliferation, invasion and migration
of HCC cells in vitro by targeting AKT1/mTOR pathway
The down-regulation of miR-149 in HCC cells and tissues
prompted us to verify whether it acted as a tumor sup-
pressor in this malignancy. As shown in Figure 5A, the
enforced expression of miR-149 significantly inhibited cell
proliferation of HepG2 cells (P = 0.01). In addition, trans-
well assays revealed that overexpression of miR-149 could
dramatically reduce the invasion activities of HepG2 cells
compared with those of control cells (P = 0.008, Figure 5B
and C). Moreover, wound-healing assays also demonstrated
Figure 4 Reverse correlation between miR-149 and AKT1 mRNA expression in human HCC tissues and cells. (A and B) Relative expression
of miR-149 and AKT1 mRNA in 130 self-pairs of HCC and adjacent nonneoplastic liver tissues; (C) Spearman Correlation analysis clearly showed a
negative correlation between miR-149 and AKT1 mRNA expression in HCC tissues (rs = −0.639, P < 0.001); (D) Spearman Correlation analysis clearly
showed a negative correlation between miR-149 and AKT1 protein expression in HCC tissues (rs = −0.716, P < 0.001); (E and F) Relative expression of
miR-149 and AKT1 mRNA HCC (HepG2) and normal liver (HL-7702) cells.
Zhang et al. Molecular Cancer 2014, 13:253 Page 7 of 15
http://www.molecular-cancer.com/content/13/1/253that overexpression of miR-149 could markedly reduce
the migration activities of HepG2 cells (P = 0.01, Figure 5D
and E).
To further verify whether the role of miR-149 in tumori-
genesis of HCC was mediated via targeting AKT1-mTORsignaling, AKT1 expression in HepG2 cells was knock-
down via siRNA, which resulted in the downregulation of
AKT1, p-AKT1, mTOR and mTOR proteins (Figure 6A
and B). Furthermore, knockdown of AKT1 expression
abolished effects of miR-149 overexpression in HepG2
Figure 5 MiR-149 inhibits cell proliferation, invasion and migration of HCC cells in vitro. (A) MTT assay showed that miR-149 overexpression
could inhibit cell proliferation of HepG2 cells. (B and C) Transwell analysis showed miR-149 overexpression could inhibit invasion of HepG2 cells.
(D and E) Scratch assays showed miR-149 overexpression could inhibit migration of HepG2 cells.
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vasion (Figure 6D) and migration (Figure 6E), indicating
that the tumor suppressive roles of miR-149 in HCC were
partially mediated by targeting AKT1-mTOR pathway.
Down-regulation of miR-149 associates the advanced
tumor progression and poor prognosis of human HCC
To evaluate whether miR-149 expression was associated
with clinicopathological features of patients with HCC,
we analyzed the association of miR-149 expression withFigure 6 MiR-149 inhibits cell proliferation, invasion and migration of
Western blot analysis of AKT1, p-AKT1, mTOR and mTOR protein expression
vectors. (C-E) Overexpression of miR-149 fails to inhibit proliferation, invasioT stage, tumor grade, presence of cirrhosis, underlying
liver disease including alcohol abuse, viral hepatitis B
and C, sex, and age (Table 1). In order to classify all 130
HCC patients into high miR-149 expression and low
miR-149 expression groups, a cutoff value for miR-149
expression levels was chosen on the basis of a measure
of heterogeneity with the log-rank test statistic with re-
spect to overall survival. As a result, there were 70 (70/
130, 53.85) patients belonging to low miR-149 expres-
sion group and 60 (60/130, 46.15%) patients belongingHCC cells in vitro by targeting AKT1/mTOR pathway. (A and B)
levels in HepG2 cells transfected with RNAi-AKT1 or RNAi-control
n, and migration in AKT1 knockdown HepG2 cells.
Table 1 Association of miR-149 expression with
clinicopathologic features of 130 hepatocellular
carcinoma patients
Clinicopathologic features Case miR-149-low (n, %) P
Age (years)
≤50 72 38 (52.78) NS
>50 58 32 (55.17)
Gender
Male 96 50 (52.08) NS
Female 34 20 (58.82)
Serum AFP
Positive 72 42 (58.33) NS
Negative 58 28 (48.28)
Tumor stage
T1 23 6 (26.09) 0.01
T2 40 15 (37.50)
T3 52 34 (65.38)
T4 15 15 (100.00)
Tumor grade
G1 31 16 (51.61) NS
G2 76 39 (51.32)
G3 23 15 (65.22)
Growth pattern
Trabecular 101 53 (52.48) NS
Nontrabecular 29 17 (58.62)
Cirrhosis
Yes 86 45 (52.33) NS
No 44 25 (56.82)
Underlying liver disease
Alcoholic 25 13 (52.00) NS
Hepatitis B 49 28 (57.14)
Hepatitis C 35 17 (48.57)
Unknown 21 12 (57.14)
Note: ‘NS’ refers to the differences among groups have no statistical significance.
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showed that the down-regulation of miR-149 was more
frequently found in HCC tissues with high tumor stage
(T3 ~ 4) than those with low tumor stage (T1 ~ 2, P = 0.01,
Table 1).
To determine the prognostic value of miR-149 in pa-
tients with HCC, the Kaplan–Meier method was employed
to analyze the correlation between miR-149 expression
with 5-year disease-free survival and 5-year overall survival
of HCC patients. As shown in Figure 7A, we observed a
trend that 5-year disease-free survival of HCC patients
with low miR-149 expression was significantly poorer than
those with high miR-149 expression (P < 0.001, log-rank
test; Figure 7A). Similarly, the Kaplan-Meier plot of 5-yearoverall survival curves stratified by miR-149 expression
also showed a significant relationship between miR-149
expression and 5-year overall survival (P < 0.001, log-rank
test, Figure 7B). Furthermore, the multivariate analysis
found that miR-149 expression was an independent
poor prognostic factor for both 5-year disease-free survival
(P = 0.003, Table 2) and 5-year overall survival (P = 0.006,
Table 2) in HCC.
Discussion
Elucidating the molecular mechanisms of tumor progres-
sion and tumor prognosis in human HCC remains largely
unexplored. In the current study, we identified 6 candidate
miRNAs targeting AKTs using an improved prediction
protocol with two steps: (1), 5 different programs for
miRNA target prediction were used due to their various
algorithms and we identified the overlap which was the
consensus among 3 out of 5 different programs; (2), we
selected miRNA-target interactions (MTIs) with low hy-
bridization energies. These two steps were performed to
minimize false positive and false negative results. Accor-
ding to the enrichment analysis on GO items and KEGG
pathways, we found that the most common functions of
the experimentally validated targets of candidate miRNAs
targeting AKTs included focal adhesion, cell cycle, p53 sig-
naling pathway, mTOR signaling pathway, apoptosis,
VEGF signaling pathway, which cover all the hallmarks of
HCC, providing a convincing evidence that these candi-
date miRNAs may have a definitive impact on hepatocar-
cinogenesis. In order to improve our understanding of this
candidate miRNAs on HCC malignant progression, we
constructed the protein interaction network of their vali-
date targets. Following the network topological analysis,
we found that AKT1 and its interaction with mTOR
respectively had the highest node-betweenness and edge-
betweenness. Many previous studies have recognized
highly connected nodes (hubs) as the most important
points in the network. Very recently, growing reports have
put forward a complementary notion that is bottlenecks
as nodes/edges with a high betweenness centrality (i.e.,
network nodes/edges which have many ‘shortest paths’
going through them). In fact, bottlenecks represent key
connector proteins/interactions with surprising functional
and dynamic properties [20]. On this context, AKT1-
mTOR may be the most important interaction in our
miRNAs-regulated protein interaction network. Thus, we
further performed a systematic experiments to validate
the regulatory effect of a candidate miRNA targeting
AKT1-miR-149 on AKT1-mTOR axis, and its involve-
ment in hepatocarcinogenesis and clinical progression of
HCC.
MiR-149, located on chromosome 2 [21], has been re-
ported to play controversial roles in the progression of
various types of human cancers. It is downregulated in
Figure 7 Disease-free survival (A) and overall survival (B) curves for two groups defined by low and high expression of miR-149 in
patients with HCC. The patients with low miR-149 expression had a significantly shorter 5-year overall and disease-free survival rate than those
with high expression (all P < 0.001).
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by targeting oncogenes. For example, Chan et al. [22] re-
ported that miR-149 could suppress breast cancer cell
migration/invasion and metastasis by targeting GIT1;
Cheng et al. [23] observed the decreased expression of
miR-149 in clear cell renal cell carcinoma; Ke et al. [24]
found that the expression of miR-149 was downregu-
lated in lung cancer and miR-149 could inhibit EMT by
targeting FOXM1; Pan et al. [18] indicated that miR-149
may play a tumor suppressive role in the proliferation
and invasion of glioma cells via blockade of the AKT1
signaling. In contrast, miR-149 is also upregulated in sev-
eral cancer cells and functions as a oncomiRs by targeting
certain tumor suppressive genes. For example, miR-149
was highly expressed in nasopharyngeal carcinoma and
promoted malignant progression by suppressing the ex-
pression of its target gene, Smad2 [25]; Its oncogenic roleTable 2 Multivariate survival analysis of five-year overall and
carcinoma




Serum AFP 1.931 0.685-4.056
Tumor stage 2.879 1.366-5.196
Tumor grade 1.563 0.609-4.088
Presence of cirrhosis 1.919 0.738-4.102
miR-149 expression 3.938 1.472-8.038was also demonstrated in melanoma in which miR-149
upregulation caused the downregulation of GSK3- and
upregulation of Mcl-1, leading to apoptotic resistance
[26]. According to miRTarBase (Release 4.5: Nov. 1, 2013;
http://mirtarbase.mbc.nctu.edu.tw/), E2F1 and MYBL2,
together with AKT1, are validated targets for miR-149.
Chen and colleagues reported that the upregulation of
E2F1 protein might associate with worse outcomes in pa-
tients with HCC [27]. Frau and colleagues also indicated
that MYBL2 upregulation could induce fast growth and
progression of premalignant and malignant liver, through
cell cycle deregulation and activation of genes and path-
ways related to tumor progression [28]. Nakajima and
colleagues identified MYBL2 as a probable transcriptional
target of E2F1 in HCC and as a useful biomarker for diag-
nosis and an attractive target for molecular therapies
useful to treat HCC [29]. In the present study, our datadisease-free survival in 130 patients with hepatocellular
Five-year disease-free survival
P HR 95% CI P
0.192 1.536 0.322-3.736 0.125
0.136 1.559 0.357-3.831 0.131
0.063 1.953 0.615-4.273 0.062
0.009 2.686 1.386-6.009 0.01
0.081 1.551 0.607-4.466 0.086
0.063 1.921 0.793-4.219 0.062
0.003 3.608 1.431-7.686 0.006
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cell line and clinical specimens compared with the normal
liver cell and matched adjacent nonneoplastic liver tissues,
respectively. In addition, our functional study showed that
AKT1 was a downstream target and effector of miR-149.
Enforced expression of miR-149 and knockdown of AKT1
both inhibited the cell proliferation and tumorigenicity of
HCC cell line in vitro. Strikingly, miR-149 overexpression
did not inhibit the cell proliferation and tumorigenicity of
HCC cells in vitro when AKT1 was knocked down. Then,
our investigation of the downstream effectors of miR-149-
AKT1 signaling axis showed that enforced expression of
miR-149 and knockdown of AKT1 both could impair the
activation of AKT1 and mTOR. Our data here provide the
first and direct evidence that miR-149 has an tumor sup-
pressive role in HCC cells by regulating AKT1/mTOR sig-
naling, which was similar with the previous findings of
Pan et al. [18] on glioma cells. More importantly, our data
showed that the expression level of miR-149 was asso-
ciated with tumor stage of HCC patients. Advance tumor
stage samples have lower miR-149 expression compared
to early tumor stage samples. These findings were similar
to the data of Wang et al. on gastric cancer [30]. Further-
more, we also identified miR-149 as an independent
prognostic factor for both 5-year disease-free survival and
5-year overall survival of HCC patients.Conclusion
This comprehensive analysis identified a list of miRNAs
targeting AKTs and revealed their critical roles in HCC
malignant progression. Especially, miR-149 may function
as a tumor suppressive miRNA and play an important
role in inhibiting the HCC tumorigenesis by modulating
the AKT/mTOR pathway. Our clinical evidence also
highlight the prognostic potential of miR-149 in HCC.
The newly identified miR-149/AKT/mTOR axis might
be a promising therapeutic target in the prevention and
treatment of HCC.Materials and methods
Prediction of miRNAs targeting AKTs
Candidate miRNAs which target AKT1, AKT2 and AKT3
were predicted by five different online programs, including
TargetScan (Release 6.2, http://www.targetscan.org/) [31],
miRDB (Last modified: April 03, 2012. http://mirdb.org/
miRDB/) [32], DIANA-microT (DIANA-microT-CDS v5.0,
http://diana.imis.athena-innovation.gr/ DianaTools/index.
php?r =microT_CDS/index) [33], miRanda (Last Update:
2010-11-01, http://www.microrna.org/microrna/home.do)
[34] and miRWalk (Last Update: 15th March 2011. http://
www.umm.uni-heidelberg.de/apps/zmf/mirwalk/) [35],
which represent different algorithms based on diverse fea-
tures, thus, their combination could ensure high specificityof the prediction. miRNAs which were commonly pre-
dicted by more than 3 out of 5 programs were retained.
Then, RNAhybrid [36] was used to calculate the MFE
of the duplex miRNA:mRNA. We chose miRNA-AKTs
interactions, MFE values of which were lower than the
median of all MFE values, as candidate miRNA-AKTs
interaction.
After that, validated targets for above candidate miR-
NAs which target AKTs were collected from miRTarBase
(Release 4.5: Nov. 1, 2013; http://mirtarbase.mbc.nctu.
edu.tw/), which has accumulated more than fifty thou-
sand MTIs [37]. Generally, the collected MTIs are
validated experimentally by reporter assay, western blot,
microarray and next-generation sequencing experiments.
Here, we only collected the MTIs which are validated
experimentally by reporter assay, western blot and
qPCR. In order to facilitate data analysis, the different
ID types for validated target genes were converted to ID
from UniProtKB-Swiss-Prot (release-2014_02).
GO and pathway enrichment analysis for validated genes
of candidate miRNAs which target AKTs
We used Database for Annotation, Visualization and Inte-
grated Discovery [38] (DAVID, http://david.abcc.ncifcrf.
gov/home.jsp,version 6.7) for GO enrichment analysis.
We also performed pathway enrichment analysis using
pathway data obtained from the FTP service of KEGG
[39] (Kyoto Encyclopedia of Genes and Genomes, http://
www.genome.jp/kegg/, Last updated: Oct 16, 2012).
Network analysis
Protein-protein interaction (PPI) data
PPI data were imported from eight existing PPI databases
including Human Annotated and Predicted Protein Inter-
action Database (HAPPI) [40], Reactome [41], Online Pre-
dicted Human Interaction Database (OPHID) [42], InAct
[43], Human Protein Reference Database (HPRD) [44],
Molecular interaction Database (MINT) [45], Database of
Interacting Proteins (DIP) [46], and PDZBase [47]. The
detailed information on these PPI databases is described
in Additional file 9: Table S8.
Network construction
Interactions between proteins encoded by validated target
genes of candidate miRNAs which target AKTs were used
to construct miRNA-regulated protein interaction net-
works. The PPI data were obtained from eight existing PPI
databases as mentioned above. Then, we applied Navigator
software (Version 2.2.1) and Cytoscape (Version 2.8.1) to
visualize the networks.
Defining network topological feature set
For each node i in miRNA-regulated protein interaction
network, we defined four measures for assessing its
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ber of links to node i; (2) ‘Node betweenness’ is defined
as the number of shortest paths between pairs of nodes
that run through node i. (3) ‘Closeness’ is defined as the
inverse of the farness which is the sum of node i
distances to all other nodes. The Closeness centrality
can be regarded as a measure of how long it will take to
spread information from node i to all other nodes se-
quentially. Degree, betweenness and closeness centra-
lities can measure a protein’s topological importance in
the network. The larger a protein’s degree/node bet-
weenness/closeness centrality is, the more important the
protein is in the PPI network [48]. (4) ‘Modularity’: pro-
teins that are highly interconnected within the network
are usually involved in the same biological modules or
pathways. Here, we used a Markov clustering algorithm
to divide all nodes into different functional modules.
For each edge in miRNA-regulated protein interaction
network, we calculated its ‘Edge Betweenness’ to assess
the importance of a specific interaction in the network.
‘Edge Betweenness’ is defined as the frequency of an
edge that places on the shortest paths between all pairs
of vertices in network [49]. The edges with highest bet-
weenness values are most likely to lie between functional
modules.
Experimental validation
Patients and Tissue Samples
The study was approved by the Research Ethics Com-
mittee of 302 Hospital of PLA, Beijing, China. Written
informed consent was obtained from all patients. All
specimens were handled and made anonymous accord-
ing to the ethical and legal standards.
A total of 130 self-pairs of HCC specimens and adjacent
nonneoplastic liver tissues were snap-frozen in liquid
nitrogen and stored at −80°C following surgery for qRT-
PCR assay. All the tissues were obtained from 130 patients
with primary HCC who underwent a curative liver resec-
tion at the 302nd Hospital of PLA, Beijing, China. These
patients were diagnosed as HCC between 2001 and 2006.
None of the patients recruited in this study had chemo-
therapy or radiotherapy before the surgery. HCC diagnosis
was based on World Health Organization (WHO) criteria.
Tumor differentiation was defined according to the
Edmondson grading system. Liver function was assessed
using the Child-Pugh scoring system. Tumor staging was
determined according to the sixth edition of the tumor-
node-metastasis (TNM) classification of the International
Union against Cancer. The clinicopathological features of
130 patients are summarized in Table 1.
The median follow-up period was 8.6 years. Postopera-
tive surveillance included routine clinical and laboratory
examinations every third month, computed tomography
scans of the abdomen, and radiographs of the chestevery third month. After 5 years, the examination inter-
val was extended to 12 months.
Cell culture
Human HCC cell line HepG2 was obtained from the
American Type Culture Collection (Manassas, VA, USA)
and was cultured in DMEM (Invitrogen, USA) supple-
mented with 10% fetal bovine serum (Gibico, USA),
2 mM L-glutamine and antibiotics. Normal human liver
cell line HL-7702 was obtained from the American Type
Culture Collection (Manassas, VA, USA) and was main-
tained in RPMI 1640 medium (Invitrogen, USA) supple-
mented with 10% fetal bovine serum (Gibico, USA).
Two cell lines were both maintained at 37°C in a
humidified chamber supplemented with 5% CO2.
Construction of miR-149 expression vectors and cellular
transfection
Commercial miR-149 mimics and miR-149 mimic control
expression vectors were purchased from Invitrogen Life
Technologies, USA. The sequence information of two vec-
tors were as following: for miR-149 mimic, 5′-UCU GGC
UCC GUG UCU UCA CUC CC-3′, for miR-149 mimic
control, 5′-GGG AGU GAA GAC ACG GAG CCA GA-3′.
HepG2 cells were transfected with miR-149 mimics and
miR-149 mimic control expression vectors with Lipofecta-
mine 2000 reagent (Invitrogen Life Technologies, USA)
according to the manufacturer’s protocol.
QRT-PCR
The qRT-PCR analysis for miRNA and mRNA was per-
formed according to the similar protocol of our previous
studies [13,50]. U6 small RNA and GAPDH were respec-
tively used as internal controls for normalization and
quantification miR-149 and AKT1 expression. The primer
sequences were listed in Additional file 10: Table S9. Rela-
tive quantification of miRNA and mRNA expression was
evaluated using the comparative cycle threshold (CT)
method. All experiments were done in triplicate. Mean
normalized gene expression ± SE was calculated from in-
dependent experiments.
RNA interference and cellular transfection
To knockdown the expression of the human Akt1 gene,
pGCSIL-GFP-Akt1 small hairpin RNA (NM_005163), an
Akt1-RNA interference (RNAi) lentiviral vector (RNAi-
AKT1), was constructed (Shanghai GeneChem Co, Ltd.,
Shanghai, China). The sense primer was 5′-CCGGGA
GGCCAAGTCCTTGCTTTCAttcaagagaTGAAAGCAAG
GACTTGGC- CTCTTTTTG-3′, and the anti-sense pri-
mer was 5′ -AATTCAAAAAGAGGCCAAGT-CCTTG
CTTTCAtctcttgaaTGAAAGCAAGGACTTGGCCTC- 3.
A scrambled short-hairpin RNA was used as a negative
control (RNAi-control). HepG2 cells were seeded into
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fected using LipofectamineTM 2000 transfection reagent
(Invitrogen) according to the manufacturer’s instructions.
The expression levels of AKT1 in HepG2 cells transfected
with RNAi-AKT1 and RNAi-control were detected by
Western blot analysis as described in the next section.
Western blot
The Western blot protocol and semiquantitative analysis
were carried out following the protocol of our previous
studies [13,50]. The specific antibodies were as following:
AKT1 antibody (#sc-1618, goat polyclonal antibody, dilu-
tion 1:150, Santa Cruz Biotechnology, Inc. USA), p-AKT1
(Ser 473) antibody (#sc-7985, rabbit polyclonal antibody,
dilution 1:150, Santa Cruz Biotechnology, Inc. USA),
mTOR antibody (#sc-1549, goat polyclonal antibody,
dilution 1:100, Santa Cruz Biotechnology, Inc. USA),
p-mTOR (Ser 2448) antibody (#sc-101738, rabbit poly-
clonal antibody, dilution 1:100, Santa Cruz Biotechnology,
Inc. USA), and GAPDH antibody (CW0266, dilution
1:1,000, CoWin Biotech). All experiments were done in
triplicate. Mean normalized gene expression ± SE was
calculated from independent experiments.
Luciferase reporter assay
The regulatory effect of miR-149 to AKT1 was evaluated
by a luciferase reporter assay in HepG2 cells following
the protocol of our previous studies [13,50]. Briefly, the
human AKT1 3′-UTR luciferase reporter construct was
generated by cloning AKT1 3′-UTR sequence containing
the predicted miR-149 binding site into the 3′-UTR
region of the pGL3 luciferase reporter vector (Promega
Corporation, Madison WI, USA). The miR-149 binding
site-deleted AKT1 3′-UTR luciferase reporter construct
was generated by PCR fragments of AKT1 3′-UTR lu-
ciferase reporter construct lacking the target site and
ligated. HepG2 cells were cultivated in 24-well plates
and co-transfected using Fugene (Roche) with 100 ng of
pGL3-AKT1-miR-149 constructs, 10 ng miR-149 mimic or
NC mimic, and 2 ng pRL-SV40 RLuci vector (Promega).
The luciferase activity assay was performed 24 h after
transfection using the dual-luciferase reporter assay system
(Promega Corporation, Madison WI) according to the
manufacturer’s instructions.
In vitro cell proliferation assay
The in vitro cell proliferation of HepG2 cells transfected
with miR-149 mimic, miR-149 mimic control, RNAi-
AKT1 and RNAi-control vectors, respectively, were
measured using the 3-(4,5-dimethylthiazol-2- yl)-2,5-
diphenyltetrazolium bromide (MTT) method following the
protocol of our previous studies [13,50]. All experiments
were done in triplicate. Mean normalized gene expression ±
SE was calculated from independent experiments.In vitro invasion and migration assay
Cell invasion and migration were respectively analyzed by
Matrigel coated transwell cell culture chambers (8 μm
pore size, Millipore, Billerica, MA, USA) and the scratch
wound-healing motility assay following the protocol of
our previous studies [13,50]. All experiments were done in
triplicate. Mean normalized gene expression ± SE was cal-
culated from independent experiments.
Statistical analysis
The software of SPSS version13.0 for Windows (SPSS Inc,
IL, USA) and SAS 9.1 (SAS Institute, Cary, NC) was used
for statistical analysis. The chi-squared test was used to
show differences in categorical variables. Patient survival
and the differences in patient survival were determined by
the Kaplan-Meier method and the log-rank test, respec-
tively. A Cox regression analysis (proportional hazard
model) was performed for the multivariate analyses of
prognostic factors. Differences were considered statisti-
cally significant when P was less than 0.05.
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